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INTRODUCTION
The devastation of Human Immunodeficiency Virus
(HIV) infection remains pronounced globally,
particularly in sub-Saharan Africa where an estimated
25.8 million people including pregnant women are
affected1. In 2010, antenatal client prevalence of HIV
in Nigeria was 4.1%2. It was reported that 90% of
paediatric HIV cases were due to mother-to-child
transmission (MTCT) of HIV3.
Literature reports that the phenomena of inflammation
and immunomodulation are involved either in HIV
infection4 or during pregnancy5, which can affect
vaccine response. Studies have highlighted the
involvement of  abnormal cellular and humoral
immune responses during HIV infection. This includes
abnormal pattern of  serum protein electrophoresis,
polyclonal hypergammaglobulinaemia, hyperproteine-
mia and plasma cell dyscrasias6,7. In addition, impaired
phagocytosis, reduced number and functions of  T-
lymphocytes were reported during pregnancy8. Despite
maternal hypergammaglobulinaemia in pregnant HIV
infected mothers, reduced IgG transplacental
transference to the foetus has been reported6,9,10, which
in turn, may influence vaccine response and neonatal
immunity.
For the protection of  mothers and babies, pregnant
women in developing countries are usually vaccinated
against tetanus. While no vaccine has yet been licenced
for the prevention of  HIV, maternal and neonatal
tetanus prophylaxis has actively been pursued by the
World Health Organization (WHO) since 198911,12.
Newborn babies are protected from neonatal tetanus
by maternal anti-tetanus antibody of the IgG class
which is transplacentally transferred from third
trimester of gestation following tetanus toxoid
vaccination in pregnant women.
Immunization for pregnant women with tetanus
toxoid vaccine is the single most effective strategy
independent of  other interventions in eliminating
neonatal tetanus11,12. However, there are conflicting
reports of the influence of maternal HIV infection on
anti-tetanus antibody production by the mothers as
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well as its transfer through the placenta to their unborn
babies. For instance, lower anti-tetanus antibody levels
in HIV infected women were reported from Senegal13
and Brazil14, but not in The Gambia15.  Cumberland
et al.6 found reduced transplacental transfer of tetanus
antibody, and about 50% lower antibody levels in cord
serum. In contrast, De Moraes-Pinto et al. from
Malawi found that maternal HIV infection had no
effect on cord anti-tetanus IgG levels as well as
transplacental transfer of anti-tetanus antibody10. In
addition, seroprevalence studies have suggested that
HIV-infected patients are less likely to have adequate
anti-tetanus antibodies. The progressive decline of  CD4
levels in HIV-infected individuals could potentially lead
to lost immunity to tetanus16,17.
With the potential for HIV infection among women
in the reproductive age group, and specifically pregnant
women, it is necessary to evaluate the effect of HIV
infection on the efficacy of tetanus toxoid in this group
of people where tetanus toxoid vaccination is
recommended. It is hypothesized that passively
transferred immunity to the developing foetus by
pregnant mothers will be affected by HIV infection.
This study assessed tetanus-specific IgG levels of cord
blood from babies born to HIV positive and negative
primigravidae who received tetanus immunization.
MATERIALS AND METHODS
This was a case-control study conducted over four
months at the labour ward of the University College
Hospital (UCH), Ibadan, Nigeria. Ethical approval was
obtained from the UI/UCH Ethical Committee (UI/
EC/11/0128). The study group consisted of  15 HIV-
infected pregnant mothers, while the control group
consisted of  age-matched HIV-negative pregnant
mothers. Maternal HIV status is routinely determined
at the antenatal booking visit. Following counselling,
HIV infection is diagnosed using rapid screening tests
and confirmed by Western Blot at the Virology
Laboratory, College of  Medicine, University of
Ibadan, Ibadan, Nigeria. Only clients who had
registered for antenatal care were recruited to ensure
that their HIV status was known. All HIV positive
clients are routinely placed on antiretroviral therapy
(ARV) as part of  antenatal care, in line with the protocol
for prevention of maternal to child transmission of
HIV. Patients were placed on Truvada (emtricitabine
and tenofovir disoproxil fumarate) and efavirenz as
from first presentation after 14 weeks of gestation.
Compliance was determined by the attending physician
enquiring from the patient how many doses had been
missed in the past one week. Patients who missed more
than one dose were referred to adherence counsellors.
The adherence counsellors would attempt to identify
any reason for non-adherence. The patient would be
assisted to develop a plan to improve adherence and
compliance. Challenges and successes with plan would
be reviewed periodically.
Consenting HIV-positive clients were recruited as
participants, when admitted in active labour. On
account of the anticipated small population, a
convenience sample of consecutive clients were
counselled until the sample size was complete. The
next consenting, age-matched, HIV-negative client who
presented in active labour (after each study group
participant), was recruited as a control. Sample size
was calculated based on the difference in antibody
transfer between HIV-positive and -negative women
obtained from a similar study18. Participants were
enrolled based on documentation in the medical
records of having received two doses of tetanus
toxoid, the second one being at least four weeks before
delivery.
A sample of 5 ml of maternal venous blood was
obtained in a universal specimen bottle without
anticoagulant. After delivery, the baby’s blood was
collected after clamping and cutting the umbilical cord.
Maternal and baby sera were separated from the
whole blood after centrifugation and stored at -200C.
A data collection tool was used to collect information
from the participants and their medical records. The
following sections were included: bio-demographic
data, HIV status, history of  index pregnancy, labour,
delivery parameters and history of tetanus toxoid
administration. The babies’ Apgar scores, birth weights
and other anthropometric parameters were also
obtained.
Cord blood tetanus specific IgG and maternal total
IgG were measured using Enzyme Linked
Immunosorbent Assay (ELISA) method with
EUROIMMUN (GMbh, Leubeck, Germany). A
fixed volume per well of appropriate sample dilution
buffer, antigen standard cocktail or an experimental
sample was pipetted into microtitre plates. This sample
was incubated at room temperature (250 C-270 C). The
ELISA immunoplate was washed 3 times with 350µl/
well of  washing buffer. A concentration of  100µl of
diluted Avidin-HRP conjugate was added, after which
the plate was incubated for 30 minutes in darkness.
The plate was washed four times and 100 µl per well
of developing solution was added. The reaction was
stopped with 100µl per well of stop solution and the
Optical Density (OD) was read at a specific wavelength
within 30 minutes of addition of stop solution. The
average absorbance of each OD was plotted against
corresponding cytokine values to create a standard
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curve. The average absorbance of  each serum sample
was used to determine corresponding cytokine values
by interpolating from the curve.
The main outcome variable was the antenatal tetanus
IgG production and transfer to babies of the
participants. All data were collected, cleaned and
manually entered into a computer. Analysis was done
using the Statistical Package for Social Sciences (SPSS)
version 17. Proportions between groups were
compared using the ÷-square test with Fisher’s exact
correction. Continuous variables were presented as
mean±SD and differences between means compared
using the students’ T-test. The level of  significance was
P<0.05.
RESULTS
The mean ages of HIV positive women (study group)
and the HIV negative women (control group) were
comparable: 28.27 ± 3.9years versus 27.32 ± 4.1years
(p = 0.688). Table 1 highlights differences in socio-
demographic variables between study and control
groups. All participants were married. Both groups
were similar in age group, occupation and educational
level.
Among the patients’ spouses, 11 (73.3%) in the study
group and 13 (86.7%) in the control group had tertiary
education (p=0.505). Eleven husbands (73.3%) were
skilled in the study group while 13(86.7%) were skilled
in the control group (p=0.174).
Tetanus immunization profile is presented in Table 2
while delivery and neonatal parameters are highlighted
in Table 3. A greater proportion of  HIV-negative
women had their second dose in the 2nd trimester [80%
v. 33%, (p=0.341)]. There was no report of  adverse
effects following immunization in either group. The
mean birth weight was 2.99 ± 3.12kg in the study group
and 2.89 ± 4.08kg in the control group (p=0.807).
There were no statistically significant relationships
between tetanus immunization profile and delivery
parameters.
Table 4 highlights the mean total IgG and tetanus
specific IgG for both groups (mothers and babies).

























Yoruba 12(80.0) 14(93.3) 0.125(4.154)
Others 3(20.0) 1(6.7)
Educational level
<Tertiary 4(26.7) 2(13.3) 0.505(1.367)
Tertiary 11(73.3) 13(86.7)
Table 1: Comparison of  socio-demographic characteristics of  HIV infected pregnant mothers compared
with HIV uninfected mothers














2nd trimester 5 (33.3) 12 (80.0) 0.341 (0.682)
3rd trimester 10 (66.7) 3 (20.0)
Table 2: Tetanus immunization record of  the participants
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Mean total IgG was not significantly different in
maternal and neonatal sera of HIV positive women
(p = 0.601 and p = 0.187 respectively) compared with
HIV non-infected controls. Mean maternal tetanus
specific IgG and cord blood tetanus specific IgG were
not significantly lower in HIV positive women when
compared with controls (p = 0.251 and p = 0.484
respectively).

















































Table 3: Comparison of  delivery mode and neonatal parameters of  the study participants












Mothers 0.71±0.13 0.77±0.12 0.251
Babies 0.72±0.12 0.76±0.16 0.484
Table 4: Serum levels of  total IgG and tetanus specific IgG in pregnant mothers infected with HIV and
cord blood of their babies compared with controls
DISCUSSION
The influence of maternal HIV on the production and
placenta transfer of maternal total IgG and tetanus-
specific IgG to the foetus was evaluated in this research.
Total maternal IgG values were higher (though not
significantly) among HIV positive women than controls
in our study. This is in support of  hypergammaglobuli-
naemia as a result of polyclonal B lymphocyte action
by HIV as previously reported4,7.
The authors of this study inferred that compliance with
antiretroviral therapy, personal hygiene and regular
antenatal care might explain the similarity in the levels
of  total IgG of  HIV-infected mothers and controls,
since the study participants were registered antenatal
clients and will likely comply with instructions.
Mean maternal tetanus-specific IgG values were not
significantly reduced in the HIV infected pregnant
mothers as found elsewhere7. In the present study, a
5% reduction from anti-tetanus IgG values in neonates
from HIV negative mothers was observed while a
study in Brazil reported a 33% reduction9. Nigerian
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studies have suggested a reduction in trans-placental
transfer of tetanus antibody by placenta malaria
parasites19 and that pregnant women are reservoirs of
Plasmodium malaria parasites especially in the placenta20.
Therefore, the presence of malaria parasites during
pregnancy might have affected the production of anti-
tetanus IgG among Nigerian subjects compared with
Brazilians, though malaria was not tested in the index
study.
Lower level of  tetanus-specific antibodies among HIV-
infected women may be due to increased lymphocyte
apoptosis and HIV-induced loss of  memory T- and
B-lymphocyte functions. Furthermore, placental
abnormalities and saturation of  active transport
receptors associated with HIV infection may also result
in inefficient transplacental antibody transfer to fetuses
of  HIV-infected women21. This may be compounded
by increased pro-inflammatory cytokines secretion and
reduced thymic sizes and lower CD4+ T-lymphocyte
counts. Our proposition is supported by the finding
that in-utero antiretroviral therapy exposure has been
associated with mitochondrial toxicity, lower numbers
of  circulating T-cell lymphocytes and neutrophils in
young infants21. Nonetheless, the slightly lower levels
of anti-tetanus antibodies in this study were not
significant.
The level of anti-tetanus antibody considered
protective by WHO guideline is >0.01U/ml 6. Our
findings indicate that antibody levels were protective
in both mother and baby pairs considered for the study.
Though majority of HIV positive women received
the 2nd tetanus immunization dose in the third trimester,
it was not likely that this significantly influenced
maternal total IgG or tetanus specific IgG. Moreover,
most viral infections affecting the mothers were found
not to cause congenital foetal infection suggesting that
the placenta may play an important role as a potent
immune-regulatory interface protecting the foetus
from systemic infection22. This modulatory effect of
the placenta might also explain non-significant
differences in the levels of total IgG and tetanus
antibody in HIV infected pregnant mothers compared
with HIV un-infected mothers.
The limitations of the study are a relatively small sample
size (though the minimum number required for the
outcome was calculated and recruited), non-screening
for placenta malaria and non-consideration of effect
of  previous vaccination on tetanus specific IgG values.
Primigravidae were recruited in an attempt to limit
the effect of previous vaccination, as multigravidae
would have been vaccinated in previous pregnancies.
CONCLUSION
HIV infection did not significantly reduce maternal
tetanus antibody production and tetanus antibody
transfer among pregnant HIV infected primigravidae
on ARV therapy in Ibadan. Adherence to antenatal
protocols, guidelines and compliance with ARV therapy
in HIV positive pregnant women must be emphasized
and periodically evaluated in all health facilities.
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